Are the specific and nonspecific ANA staining patterns of Behçet's Disease patients important?

BACKGROUND: The autoinflammatory character of Behçet's Disease has led researchers to investigate the role of autoantibodies. However, no significant positive result has been reported for autoantibody tests for the disease. AIMS: To investigate the specific and nonspecific staining patterns of Behçet's Disease (BD) patients. METHODS: 140 patients (87 females, 53 males) with an average of 41.9±3 years who were being followed up for Behçet's Disease, and a control group consisting of a total of 736 (464 females, 272 males) healthy volunteers made up of blood donors without any disease whose average age was 50.2±4 years were included in the study. Peripheral venous blood was collected from the patients and the sera were separated. Patient sera were studied by indirect immunofluorescence antibody test (IFA) at a dilution of 1/40 and 1/100. RESULTS: A total of 140 (87 females, 53 males) Behçet's Disease patients and 736 (464 females, 272 males) healthy controls were examined. The rate of ANA positivity was 11.6% in the control group and 10.7% in the Behçet's Disease group. In general, no difference was detected between the patients and the healthy controls in terms of autoantibody positivity (p>0.05). However, when examined in terms of patterns, the low detection of DFS70 and the observation of centriole staining type patterns in Behçet's Disease patients was noteworthy (p<0.05). CONCLUSION: Autoantibody tests, which hold an important place in classic autoimmune diseases, are not necessary for Behçet's patients, but they should be examined in terms of nonspecific patterns.

Are the specific and nonspecific ANA staining patterns of Behçet's Disease patients important? / ¿Son importantes los patrones de tinción ANA específicos y no específicos para los pacientes con enfermedad de Behçet?

Background: The autoinflammatory character of Behçet's Disease has led researchers to investigate the role of autoantibodies. However, no significant positive result has been reported for autoantibody tests for the disease. Aims: To investigate the specific and nonspecific staining patterns of Behçet's Disease (BD) patients. Methods: 140 patients (87 females, 53 males) with an average of 41.9±3 years who were being followed up for Behçet's Disease, and a control group consisting of a total of 736 (464 females, 272 males) healthy volunteers made up of blood donors without any disease whose average age was 50.2±4 years were included in the study. Peripheral venous blood was collected from the patients and the sera were separated. Patient sera were studied by indirect immunofluorescence antibody test (IFA) at a dilution of 1/40 and 1/100. Results: A total of 140 (87 females, 53 males) Behçet's Disease patients and 736 (464 females, 272 males) healthy controls were examined. The rate of ANA positivity was 11.6% in the control group and 10.7% in the Behçet's Disease group. In general, no difference was detected between the patients and the healthy controls in terms of autoantibody positivity (p>0.05). However, when examined in terms of patterns, the low detection of DFS70 and the observation of centriole staining type patterns in Behçet's Disease patients was noteworthy (p<0.05). Conclusion: Autoantibody tests, which hold an important place in classic autoimmune diseases, are not necessary for Behçet's patients, but they should be examined in terms of nonspecific patterns.(AU)

Antecedentes: El carácter autoinflamatorio de la enfermedad de Behçet (EB) ha llevado a los investigadores a estudiar el rol de los autoanticuerpos. Sin embargo, no se ha reportado un resultado positivo significativo para las pruebas de autoanticuerpos. Objetivo: Investigar los patrones de tinción específicos y no específicos de los pacientes con EB. Métodos: Se incluyó en el estudio a 140 pacientes (87 mujeres y 53 varones) con una edad media de 41,9±3 años con seguimiento por EB, y un grupo control que incluyó a un total de 736 voluntarios sanos (464 mujeres y 272 varones) integrados por donantes de sangre sin enfermedad alguna, con una edad media de 50,2±4 años. Se extrajo sangre de vena periférica a todos los pacientes, separándose el suero, que se estudió mediante el test de anticuerpos por inmunofluorescencia directa (IFA) a un factor de dilución de 1/40 y 1/100. Resultados: Se examinó a un total de 140 pacientes (87 mujeres y 53 varones) con EB y 736 controles sanos (464 mujeres y 272 varones). La tasa de positividad de ANA fue del 11,6% en el grupo control y del 10,7% en el grupo de EB. En general no se detectó diferencia entre los pacientes y los controles sanos en términos de positividad de autoanticuerpos (p>0,05). Sin embargo, al realizarse el examen en términos de patrones, fue destacable la baja detección de DFS70 y la observación de los patrones tipo tinción de centriolos en los pacientes con EB (p<0,05). Conclusión: Los test de autoanticuerpos, que ocupan una posición importante en las enfermedades autoinmunes clásicas, no son necesarios para los pacientes con EB, aunque deberían examinarse en términos de patrones no específicos.(AU)

Are the Specific and Nonspecific ANA Staining Patterns of Behçet's Disease Patients Important?

BACKGROUND: The autoinflammatory character of Behçet's Disease has led researchers to investigate the role of autoantibodies. However, no significant positive result has been reported for autoantibody tests for the disease. AIMS: To investigate the specific and nonspecific staining patterns of Behçet's Disease (BD) patients. METHODS: 140 patients (87 females, 53 males) with an average of 41.9±3 years who were being followed up for Behçet's Disease, and a control group consisting of a total of 736 (464 females, 272 males) healthy volunteers made up of blood donors without any disease whose average age was 50.2±4 years were included in the study. Peripheral venous blood was collected from the patients and the sera were separated. Patient sera were studied by indirect immunofluorescence antibody test (IFA) at a dilution of 1/40 and 1/100. RESULTS: A total of 140 (87 females, 53 males) Behçet's Disease patients and 736 (464 females, 272 males) healthy controls were examined. The rate of ANA positivity was 11.6% in the control group and 10.7% in the Behçet's Disease group. In general, no difference was detected between the patients and the healthy controls in terms of autoantibody positivity (p>0.05). However, when examined in terms of patterns, the low detection of DFS70 and the observation of centriole staining type patterns in Behçet's Disease patients was noteworthy (p<0.05). CONCLUSION: Autoantibody tests, which hold an important place in classic autoimmune diseases, are not necessary for Behçet's patients, but they should be examined in terms of nonspecific patterns.

No association of PTPN22 R620W gene polymorphism with rheumatic heart disease and systemic lupus erythematosus.

Rheumatic heart disease (RHD) or acute rheumatic fever (ARF) develops as a consequence of an exaggerated immune response to Group A beta haemolytic streptococci causing pharyngitis. The molecular mimicry appears between human cardiac myosin and M protein of group A streptococcal membranes. The polymorphism of the protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene, which encodes an important negative regulator of T cell activation, has been reported to be associated with susceptibility to several autoimmune diseases such as SLE and RA. The objective of this study was to investigate whether PTPN22 R620W polymorphism confers susceptibility to RHD in Turkish population. PTPN 22 R620W (rs2476601, A/G) polymorphism was genotyped by PCR-RFLP in 121 patients with RHD who fulfilling the revised classification criteria of Jones, and 160 healthy control (HC), and also 137 SLE as a diseased-control. The frequency of GG and AG genotypes were found to be 94% (114), 6% (7) in RHD, respectively and 96% (153) and 4% (7) in HC, respectively. The homozygous AA genotype was not present in RHD and HC. There was no statistically significant difference between RHD and HC according to the frequency of AG heterozygote genotype (P = 0.831; OR = 1.13; 95% CI 0.37-3.46). The frequency of the rare allele A was also very similar in RHD patients and HC (3, 2% respectively). A similar result was also found between SLE and HC. Our results demonstrated that the PTPN22 R620W polymorphism is not associated with RHD nor with SLE in Turkish population.